| Outgoing Relation(s) |
| vasoconstrictor agent (CHEBI:50514) is a cardiovascular drug (CHEBI:35554) |
| Incoming Relation(s) |
| (R)-adrenaline (CHEBI:28918) has role vasoconstrictor agent (CHEBI:50514) |
| (R)-noradrenaline (CHEBI:18357) has role vasoconstrictor agent (CHEBI:50514) |
| (−)-ephedrine (CHEBI:15407) has role vasoconstrictor agent (CHEBI:50514) |
| (8S,9R)-EET (CHEBI:132302) has role vasoconstrictor agent (CHEBI:50514) |
| P1,P5-bis(5'-adenosyl) pentaphosphate (CHEBI:28898) has role vasoconstrictor agent (CHEBI:50514) |
| P1,P6-bis(5'-adenosyl)hexaphosphate (CHEBI:63689) has role vasoconstrictor agent (CHEBI:50514) |
| 8-epi-prostaglandin E2 (CHEBI:131888) has role vasoconstrictor agent (CHEBI:50514) |
| 8-epi-prostaglandin F2α (CHEBI:34505) has role vasoconstrictor agent (CHEBI:50514) |
| almotriptan (CHEBI:520985) has role vasoconstrictor agent (CHEBI:50514) |
| almotriptan malate (CHEBI:53781) has role vasoconstrictor agent (CHEBI:50514) |
| angiotensin II (CHEBI:48432) has role vasoconstrictor agent (CHEBI:50514) |
| caesium chloride (CHEBI:63039) has role vasoconstrictor agent (CHEBI:50514) |
| carbocyclic thromboxane A2 (CHEBI:139043) has role vasoconstrictor agent (CHEBI:50514) |
| cocaine (CHEBI:27958) has role vasoconstrictor agent (CHEBI:50514) |
| deglymidodrine (CHEBI:73248) has role vasoconstrictor agent (CHEBI:50514) |
| dihydroergotamine (CHEBI:4562) has role vasoconstrictor agent (CHEBI:50514) |
| dihydroergotamine mesylate (CHEBI:59756) has role vasoconstrictor agent (CHEBI:50514) |
| dihydroergotamine tartrate (CHEBI:59757) has role vasoconstrictor agent (CHEBI:50514) |
| droxidopa (CHEBI:31524) has role vasoconstrictor agent (CHEBI:50514) |
| eletriptan (CHEBI:50922) has role vasoconstrictor agent (CHEBI:50514) |
| eletriptan hydrobromide (CHEBI:61176) has role vasoconstrictor agent (CHEBI:50514) |
| ergotamine (CHEBI:64318) has role vasoconstrictor agent (CHEBI:50514) |
| FE201874 (CHEBI:234125) has role vasoconstrictor agent (CHEBI:50514) |
| felypressin (CHEBI:60564) has role vasoconstrictor agent (CHEBI:50514) |
| leukotriene B4 (CHEBI:15647) has role vasoconstrictor agent (CHEBI:50514) |
| metaraminol (CHEBI:6794) has role vasoconstrictor agent (CHEBI:50514) |
| methysergide (CHEBI:584020) has role vasoconstrictor agent (CHEBI:50514) |
| midodrine (CHEBI:6933) has role vasoconstrictor agent (CHEBI:50514) |
| midodrine hydrochloride (CHEBI:31847) has role vasoconstrictor agent (CHEBI:50514) |
| mometasone (CHEBI:6970) has role vasoconstrictor agent (CHEBI:50514) |
| naratriptan (CHEBI:7478) has role vasoconstrictor agent (CHEBI:50514) |
| oxymetazoline (CHEBI:7862) has role vasoconstrictor agent (CHEBI:50514) |
| oxymetazoline hydrochloride (CHEBI:7863) has role vasoconstrictor agent (CHEBI:50514) |
| PD123319 (CHEBI:61014) has role vasoconstrictor agent (CHEBI:50514) |
| phenylephrine (CHEBI:8093) has role vasoconstrictor agent (CHEBI:50514) |
| pseudoephedrine (CHEBI:51209) has role vasoconstrictor agent (CHEBI:50514) |
| rizatriptan (CHEBI:48273) has role vasoconstrictor agent (CHEBI:50514) |
| sumatriptan (CHEBI:10650) has role vasoconstrictor agent (CHEBI:50514) |
| sumatriptan succinate (CHEBI:64359) has role vasoconstrictor agent (CHEBI:50514) |
| tetrahydrozoline hydrochloride (CHEBI:9492) has role vasoconstrictor agent (CHEBI:50514) |
| tetrahydrozoline nitrate (CHEBI:145570) has role vasoconstrictor agent (CHEBI:50514) |
| U0126 (CHEBI:90693) has role vasoconstrictor agent (CHEBI:50514) |
| U0126.EtOH (CHEBI:90692) has role vasoconstrictor agent (CHEBI:50514) |
| zolmitriptan (CHEBI:10124) has role vasoconstrictor agent (CHEBI:50514) |
| α-methylnoradrenaline (CHEBI:141146) has role vasoconstrictor agent (CHEBI:50514) |
